Christopher DeSouza
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cell-Derived Microparticles | 19 | 2026 | 73 | 10.610 |
Why?
| | Endothelium, Vascular | 49 | 2026 | 959 | 10.130 |
Why?
| | Endothelial Cells | 23 | 2026 | 886 | 7.780 |
Why?
| | Vasodilation | 31 | 2025 | 522 | 6.320 |
Why?
| | Endothelin-1 | 20 | 2026 | 181 | 5.880 |
Why?
| | Fibrinolysis | 18 | 2026 | 164 | 4.730 |
Why?
| | Tissue Plasminogen Activator | 22 | 2026 | 248 | 4.130 |
Why?
| | Vasoconstriction | 14 | 2025 | 216 | 3.760 |
Why?
| | Microvessels | 5 | 2026 | 98 | 3.450 |
Why?
| | Nitric Oxide | 17 | 2026 | 892 | 3.180 |
Why?
| | Obesity | 22 | 2026 | 3149 | 3.020 |
Why?
| | Aging | 42 | 2026 | 1992 | 2.900 |
Why?
| | Human Umbilical Vein Endothelial Cells | 8 | 2025 | 105 | 2.870 |
Why?
| | Vasodilator Agents | 23 | 2025 | 330 | 2.740 |
Why?
| | Extracellular Vesicles | 5 | 2026 | 175 | 2.690 |
Why?
| | Forearm | 19 | 2025 | 141 | 2.660 |
Why?
| | Nitric Oxide Synthase Type III | 11 | 2026 | 203 | 2.590 |
Why?
| | Hypertension | 14 | 2023 | 1280 | 2.580 |
Why?
| | Spinal Cord Injuries | 5 | 2025 | 240 | 2.440 |
Why?
| | Sleep Deprivation | 6 | 2021 | 207 | 2.410 |
Why?
| | MicroRNAs | 9 | 2026 | 694 | 2.230 |
Why?
| | Apoptosis | 17 | 2026 | 2454 | 2.120 |
Why?
| | Overweight | 9 | 2018 | 617 | 1.950 |
Why?
| | Acetylcholine | 18 | 2025 | 209 | 1.890 |
Why?
| | Exercise | 35 | 2026 | 2219 | 1.730 |
Why?
| | Middle Aged | 118 | 2026 | 36821 | 1.730 |
Why?
| | Prehypertension | 5 | 2015 | 27 | 1.600 |
Why?
| | Regional Blood Flow | 24 | 2025 | 514 | 1.580 |
Why?
| | Brain | 5 | 2026 | 3009 | 1.560 |
Why?
| | Vasomotor System | 2 | 2025 | 47 | 1.510 |
Why?
| | Blood Pressure | 20 | 2021 | 1785 | 1.460 |
Why?
| | Oxidative Stress | 10 | 2026 | 1368 | 1.450 |
Why?
| | Cardiovascular Diseases | 11 | 2021 | 2218 | 1.440 |
Why?
| | HIV Envelope Protein gp120 | 3 | 2019 | 55 | 1.430 |
Why?
| | Polycythemia | 2 | 2021 | 25 | 1.330 |
Why?
| | Stem Cells | 8 | 2012 | 630 | 1.290 |
Why?
| | Sleep | 5 | 2021 | 895 | 1.250 |
Why?
| | Cells, Cultured | 13 | 2026 | 4169 | 1.250 |
Why?
| | Male | 99 | 2026 | 73950 | 1.210 |
Why?
| | Postmenopause | 18 | 2023 | 394 | 1.170 |
Why?
| | Caspase 3 | 6 | 2026 | 242 | 1.160 |
Why?
| | NG-Nitroarginine Methyl Ester | 3 | 2024 | 49 | 1.150 |
Why?
| | Nitroprusside | 16 | 2021 | 71 | 1.150 |
Why?
| | Enzyme Inhibitors | 6 | 2024 | 822 | 1.120 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 25 | 1.120 |
Why?
| | Humans | 147 | 2026 | 147293 | 1.110 |
Why?
| | Circulating MicroRNA | 2 | 2019 | 26 | 1.090 |
Why?
| | C-Reactive Protein | 7 | 2015 | 430 | 1.080 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 365 | 1.050 |
Why?
| | Atherosclerosis | 2 | 2023 | 411 | 1.010 |
Why?
| | Nebivolol | 2 | 2017 | 9 | 1.010 |
Why?
| | Cell Movement | 8 | 2014 | 966 | 0.990 |
Why?
| | Aged | 70 | 2026 | 26514 | 0.980 |
Why?
| | Physical Endurance | 17 | 2026 | 279 | 0.960 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 50 | 0.960 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 273 | 0.950 |
Why?
| | Adult | 72 | 2026 | 41405 | 0.940 |
Why?
| | Female | 90 | 2026 | 80076 | 0.930 |
Why?
| | Inflammation Mediators | 5 | 2024 | 507 | 0.910 |
Why?
| | Erythritol | 1 | 2025 | 2 | 0.900 |
Why?
| | Estradiol | 2 | 2026 | 515 | 0.900 |
Why?
| | Sweetening Agents | 1 | 2025 | 57 | 0.860 |
Why?
| | Vasoconstrictor Agents | 6 | 2023 | 150 | 0.830 |
Why?
| | Work-Life Balance | 1 | 2024 | 23 | 0.820 |
Why?
| | Reactive Oxygen Species | 5 | 2026 | 616 | 0.810 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 92 | 0.800 |
Why?
| | Case-Control Studies | 13 | 2026 | 3660 | 0.760 |
Why?
| | Goals | 1 | 2024 | 186 | 0.740 |
Why?
| | Dietary Fats | 2 | 2015 | 309 | 0.730 |
Why?
| | Bradykinin | 9 | 2025 | 49 | 0.720 |
Why?
| | Blood Coagulation | 2 | 2021 | 274 | 0.700 |
Why?
| | Estrogen Replacement Therapy | 9 | 2003 | 144 | 0.660 |
Why?
| | Biomarkers | 14 | 2026 | 4351 | 0.660 |
Why?
| | Vascular Diseases | 1 | 2023 | 252 | 0.650 |
Why?
| | Altitude | 3 | 2021 | 470 | 0.640 |
Why?
| | Physical Fitness | 12 | 2005 | 209 | 0.600 |
Why?
| | Acclimatization | 1 | 2021 | 170 | 0.590 |
Why?
| | Blood Platelets | 2 | 2026 | 381 | 0.580 |
Why?
| | Hemodynamics | 8 | 2021 | 1127 | 0.570 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 421 | 0.560 |
Why?
| | Cross-Sectional Studies | 23 | 2023 | 6011 | 0.550 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2030 | 0.550 |
Why?
| | Ascorbic Acid | 3 | 2021 | 184 | 0.550 |
Why?
| | Endothelium | 3 | 2020 | 119 | 0.550 |
Why?
| | Young Adult | 15 | 2026 | 14437 | 0.540 |
Why?
| | Telomere | 3 | 2010 | 298 | 0.530 |
Why?
| | Metoprolol | 1 | 2017 | 26 | 0.530 |
Why?
| | HIV | 1 | 2019 | 251 | 0.520 |
Why?
| | Plethysmography | 5 | 2017 | 104 | 0.520 |
Why?
| | Hematopoietic Stem Cells | 2 | 2011 | 435 | 0.510 |
Why?
| | Blood Glucose | 7 | 2019 | 2359 | 0.500 |
Why?
| | Hyperglycemia | 2 | 2018 | 381 | 0.500 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 60 | 0.490 |
Why?
| | Stress, Physiological | 2 | 2017 | 445 | 0.490 |
Why?
| | Plasminogen Activator Inhibitor 1 | 7 | 2023 | 85 | 0.480 |
Why?
| | Cytokines | 4 | 2020 | 2086 | 0.480 |
Why?
| | Age Factors | 10 | 2026 | 3372 | 0.470 |
Why?
| | Body Mass Index | 15 | 2017 | 2470 | 0.460 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 234 | 0.460 |
Why?
| | HIV Infections | 4 | 2019 | 3235 | 0.450 |
Why?
| | Cellular Senescence | 1 | 2018 | 229 | 0.450 |
Why?
| | Interleukin-6 | 6 | 2025 | 784 | 0.440 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 145 | 0.440 |
Why?
| | Gender Identity | 2 | 2006 | 133 | 0.430 |
Why?
| | Diet, High-Fat | 2 | 2018 | 267 | 0.420 |
Why?
| | Oxygen Consumption | 13 | 2026 | 721 | 0.400 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 20 | 0.400 |
Why?
| | Interleukin-8 | 3 | 2025 | 269 | 0.400 |
Why?
| | Analysis of Variance | 7 | 2016 | 1302 | 0.390 |
Why?
| | Glucose | 2 | 2017 | 1051 | 0.390 |
Why?
| | Adiposity | 3 | 2016 | 533 | 0.390 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 61 | 0.370 |
Why?
| | Colony-Forming Units Assay | 6 | 2014 | 95 | 0.370 |
Why?
| | Blood Vessels | 1 | 2014 | 167 | 0.370 |
Why?
| | Transcription Factor RelA | 2 | 2024 | 93 | 0.370 |
Why?
| | Arteries | 7 | 2018 | 262 | 0.360 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.360 |
Why?
| | Alkalosis, Respiratory | 2 | 2023 | 2 | 0.360 |
Why?
| | Coronary Disease | 3 | 2007 | 382 | 0.360 |
Why?
| | Body Composition | 14 | 2009 | 694 | 0.350 |
Why?
| | Glucose Intolerance | 1 | 2013 | 142 | 0.350 |
Why?
| | Inflammation | 5 | 2025 | 2920 | 0.350 |
Why?
| | T-Lymphocytes | 2 | 2010 | 2017 | 0.340 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2010 | 450 | 0.340 |
Why?
| | NF-kappa B | 3 | 2025 | 676 | 0.340 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 919 | 0.330 |
Why?
| | Flow Cytometry | 5 | 2026 | 1172 | 0.330 |
Why?
| | Abdominal Fat | 1 | 2011 | 51 | 0.330 |
Why?
| | Time Factors | 10 | 2021 | 7173 | 0.330 |
Why?
| | Fatty Acids | 1 | 2014 | 461 | 0.330 |
Why?
| | Antigens, CD34 | 1 | 2011 | 90 | 0.330 |
Why?
| | Muscle Tonus | 2 | 2010 | 24 | 0.320 |
Why?
| | Sex Characteristics | 5 | 2026 | 799 | 0.320 |
Why?
| | HIV Protease Inhibitors | 1 | 2011 | 70 | 0.320 |
Why?
| | Risk Factors | 14 | 2018 | 11017 | 0.310 |
Why?
| | Dyslipidemias | 1 | 2012 | 185 | 0.310 |
Why?
| | Chemotaxis | 1 | 2010 | 122 | 0.310 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 363 | 0.310 |
Why?
| | Health | 1 | 2010 | 82 | 0.300 |
Why?
| | HIV-1 | 2 | 2019 | 917 | 0.300 |
Why?
| | Postprandial Period | 3 | 2019 | 115 | 0.300 |
Why?
| | Disease | 1 | 2010 | 96 | 0.300 |
Why?
| | Heart Failure | 1 | 2023 | 2334 | 0.290 |
Why?
| | Feeding Behavior | 1 | 2015 | 693 | 0.280 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 552 | 0.280 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 315 | 0.280 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 14 | 0.270 |
Why?
| | Phosphorylation | 2 | 2024 | 1721 | 0.270 |
Why?
| | Fasting | 4 | 2019 | 280 | 0.260 |
Why?
| | Reference Values | 7 | 2016 | 800 | 0.260 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 29 | 0.250 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 61 | 0.250 |
Why?
| | Platelet Membrane Glycoprotein IIb | 1 | 2026 | 5 | 0.240 |
Why?
| | Superoxide Dismutase-1 | 1 | 2026 | 13 | 0.240 |
Why?
| | Adult Stem Cells | 1 | 2006 | 40 | 0.240 |
Why?
| | Exercise Therapy | 4 | 2017 | 489 | 0.240 |
Why?
| | Annexin A1 | 1 | 2026 | 8 | 0.240 |
Why?
| | Catalase | 1 | 2026 | 134 | 0.240 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2026 | 2627 | 0.240 |
Why?
| | Running | 6 | 2026 | 234 | 0.230 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 6 | 0.230 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 708 | 0.220 |
Why?
| | Hyperthermia, Induced | 2 | 2023 | 120 | 0.220 |
Why?
| | Double-Blind Method | 5 | 2021 | 2080 | 0.220 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 287 | 0.210 |
Why?
| | Cardiovascular System | 1 | 2026 | 139 | 0.210 |
Why?
| | Walking | 5 | 2018 | 549 | 0.210 |
Why?
| | Premenopause | 5 | 2002 | 129 | 0.210 |
Why?
| | Physiology | 1 | 2024 | 13 | 0.210 |
Why?
| | Superoxide Dismutase | 1 | 2026 | 308 | 0.210 |
Why?
| | Adipose Tissue | 6 | 2005 | 646 | 0.210 |
Why?
| | Blood Flow Velocity | 3 | 2012 | 422 | 0.200 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 12 | 0.200 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 154 | 0.200 |
Why?
| | Quadriplegia | 1 | 2023 | 14 | 0.200 |
Why?
| | Carotid Arteries | 5 | 2003 | 208 | 0.200 |
Why?
| | Signal Transduction | 5 | 2025 | 5272 | 0.200 |
Why?
| | Women's Health | 1 | 2026 | 317 | 0.200 |
Why?
| | Colorado | 7 | 2026 | 4591 | 0.200 |
Why?
| | Hypertrophy | 2 | 2023 | 128 | 0.200 |
Why?
| | Antihypertensive Agents | 4 | 2013 | 522 | 0.190 |
Why?
| | Actinin | 1 | 2023 | 12 | 0.190 |
Why?
| | von Willebrand Factor | 1 | 2023 | 85 | 0.190 |
Why?
| | Thrombophilia | 1 | 2023 | 89 | 0.190 |
Why?
| | Troponin T | 1 | 2023 | 63 | 0.190 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 37 | 0.180 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 43 | 0.180 |
Why?
| | Career Choice | 1 | 2024 | 237 | 0.180 |
Why?
| | Vaping | 1 | 2023 | 81 | 0.170 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 112 | 0.170 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.170 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.170 |
Why?
| | Aged, 80 and over | 7 | 2026 | 8430 | 0.170 |
Why?
| | Respiratory Muscles | 1 | 2021 | 37 | 0.170 |
Why?
| | Diet, Sodium-Restricted | 1 | 2001 | 39 | 0.170 |
Why?
| | South America | 1 | 2021 | 56 | 0.170 |
Why?
| | Peru | 1 | 2021 | 61 | 0.170 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2018 | 38 | 0.160 |
Why?
| | Lymphocyte Count | 2 | 2011 | 165 | 0.160 |
Why?
| | Endothelins | 1 | 2021 | 61 | 0.160 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 789 | 0.160 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 38 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2015 | 1224 | 0.160 |
Why?
| | Fibrosis | 1 | 2023 | 568 | 0.160 |
Why?
| | Cytochromes c | 2 | 2010 | 53 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 475 | 0.160 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 86 | 0.150 |
Why?
| | Piperidines | 2 | 2013 | 224 | 0.150 |
Why?
| | Fibrinogen | 2 | 1998 | 180 | 0.150 |
Why?
| | Oligopeptides | 2 | 2013 | 267 | 0.150 |
Why?
| | Physical Exertion | 2 | 1998 | 205 | 0.150 |
Why?
| | Fever | 2 | 2020 | 320 | 0.150 |
Why?
| | Insulin Glargine | 1 | 2019 | 88 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2006 | 2529 | 0.140 |
Why?
| | Chronic Disease | 1 | 2025 | 1844 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 221 | 0.140 |
Why?
| | E-Selectin | 1 | 2018 | 61 | 0.140 |
Why?
| | HIV Antibodies | 1 | 2019 | 61 | 0.140 |
Why?
| | Hemoglobins | 1 | 2021 | 386 | 0.140 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 430 | 0.140 |
Why?
| | Telomerase | 2 | 2011 | 250 | 0.140 |
Why?
| | Brachial Artery | 3 | 2017 | 209 | 0.140 |
Why?
| | Phenotype | 2 | 2021 | 3216 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2023 | 547 | 0.140 |
Why?
| | Heat-Shock Response | 1 | 2018 | 78 | 0.130 |
Why?
| | Antioxidants | 1 | 2021 | 550 | 0.130 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 9 | 0.130 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 42 | 0.130 |
Why?
| | Dietary Carbohydrates | 1 | 2018 | 147 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5476 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 132 | 0.130 |
Why?
| | Biomedical Research | 1 | 2024 | 723 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2005 | 1213 | 0.130 |
Why?
| | Heart | 1 | 2021 | 628 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1912 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2021 | 11947 | 0.120 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 20 | 0.120 |
Why?
| | Lipids | 3 | 2009 | 723 | 0.120 |
Why?
| | Anthropometry | 2 | 2011 | 206 | 0.120 |
Why?
| | Prognosis | 3 | 2018 | 4383 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2017 | 762 | 0.120 |
Why?
| | Triglycerides | 3 | 2005 | 529 | 0.110 |
Why?
| | Baroreflex | 3 | 2001 | 57 | 0.110 |
Why?
| | Substance P | 2 | 2008 | 38 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 618 | 0.110 |
Why?
| | Isoproterenol | 2 | 2008 | 96 | 0.110 |
Why?
| | Insulin | 2 | 2005 | 2526 | 0.110 |
Why?
| | Blood Circulation | 1 | 2015 | 44 | 0.110 |
Why?
| | Insulin Resistance | 2 | 2003 | 1253 | 0.110 |
Why?
| | Interleukin-18 | 2 | 2006 | 234 | 0.110 |
Why?
| | Hot Temperature | 1 | 2017 | 396 | 0.100 |
Why?
| | Cross-Over Studies | 4 | 2017 | 617 | 0.100 |
Why?
| | Regression Analysis | 5 | 2011 | 1003 | 0.100 |
Why?
| | Peptides | 1 | 2019 | 1003 | 0.100 |
Why?
| | Cardiovascular Physiological Phenomena | 2 | 2026 | 49 | 0.100 |
Why?
| | Physical Education and Training | 2 | 2024 | 70 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 311 | 0.090 |
Why?
| | Hydrocortisone | 1 | 2015 | 300 | 0.090 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 8 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 198 | 0.090 |
Why?
| | Blood Volume | 4 | 1999 | 65 | 0.080 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 48 | 0.080 |
Why?
| | Waist Circumference | 1 | 2011 | 146 | 0.080 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 61 | 0.080 |
Why?
| | Vital Capacity | 2 | 2002 | 293 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 187 | 0.080 |
Why?
| | Femoral Artery | 2 | 2002 | 190 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2015 | 514 | 0.080 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.080 |
Why?
| | Staurosporine | 1 | 2010 | 22 | 0.080 |
Why?
| | Prevalence | 3 | 2014 | 2889 | 0.080 |
Why?
| | Cholesterol | 2 | 2005 | 410 | 0.080 |
Why?
| | Estrogens | 2 | 2003 | 368 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1415 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 59 | 0.080 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 90 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 200 | 0.070 |
Why?
| | Cell Separation | 1 | 2010 | 306 | 0.070 |
Why?
| | CD3 Complex | 1 | 2009 | 113 | 0.070 |
Why?
| | Leg | 2 | 2001 | 243 | 0.070 |
Why?
| | Cerebrovascular Circulation | 2 | 2023 | 293 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 383 | 0.070 |
Why?
| | Up-Regulation | 1 | 2012 | 848 | 0.070 |
Why?
| | Norepinephrine | 1 | 2009 | 201 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 440 | 0.070 |
Why?
| | Life Style | 5 | 2003 | 504 | 0.070 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.070 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 32 | 0.070 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 63 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 22825 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 321 | 0.070 |
Why?
| | Methacholine Chloride | 1 | 2008 | 51 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 166 | 0.060 |
Why?
| | Hemiplegia | 2 | 1997 | 20 | 0.060 |
Why?
| | Arm | 1 | 2007 | 110 | 0.060 |
Why?
| | Coronary Circulation | 1 | 2007 | 134 | 0.060 |
Why?
| | Probability | 1 | 2007 | 309 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 119 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3784 | 0.060 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2005 | 17 | 0.060 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.060 |
Why?
| | Muscle, Skeletal | 3 | 2002 | 1798 | 0.050 |
Why?
| | DNA Methylation | 1 | 2010 | 722 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 448 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2005 | 325 | 0.050 |
Why?
| | Anaerobic Threshold | 2 | 2005 | 29 | 0.050 |
Why?
| | France | 1 | 2024 | 40 | 0.050 |
Why?
| | Hypocapnia | 1 | 2023 | 9 | 0.050 |
Why?
| | Hyperventilation | 1 | 2023 | 15 | 0.050 |
Why?
| | Weight Loss | 1 | 2010 | 867 | 0.050 |
Why?
| | Thrombosis | 1 | 2007 | 401 | 0.050 |
Why?
| | Monocytes | 1 | 2026 | 539 | 0.050 |
Why?
| | History, 21st Century | 1 | 2024 | 227 | 0.050 |
Why?
| | Compliance | 4 | 2008 | 50 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 976 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 28 | 0.050 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 30 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 333 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1077 | 0.050 |
Why?
| | Adenine | 1 | 2005 | 339 | 0.050 |
Why?
| | Bicycling | 1 | 2024 | 119 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 45 | 0.050 |
Why?
| | Heart Rate | 4 | 2001 | 860 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 615 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 2017 | 0.040 |
Why?
| | Athletes | 1 | 2026 | 431 | 0.040 |
Why?
| | Exercise Test | 3 | 2005 | 636 | 0.040 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 92 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 228 | 0.040 |
Why?
| | Progesterone | 1 | 2003 | 215 | 0.040 |
Why?
| | Carotid Artery Diseases | 1 | 2002 | 70 | 0.040 |
Why?
| | Universities | 1 | 2024 | 453 | 0.040 |
Why?
| | Tunica Intima | 4 | 2002 | 79 | 0.040 |
Why?
| | Systole | 1 | 2001 | 181 | 0.040 |
Why?
| | Heart Conduction System | 1 | 2001 | 96 | 0.040 |
Why?
| | Ultrasonography | 5 | 2002 | 795 | 0.040 |
Why?
| | Mexican Americans | 1 | 2001 | 119 | 0.040 |
Why?
| | Knee | 1 | 2000 | 73 | 0.040 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2019 | 16 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2133 | 0.040 |
Why?
| | Hemorheology | 1 | 2018 | 24 | 0.040 |
Why?
| | Social Class | 1 | 2001 | 266 | 0.040 |
Why?
| | Body Constitution | 1 | 1998 | 51 | 0.040 |
Why?
| | Energy Intake | 2 | 1998 | 514 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2018 | 79 | 0.030 |
Why?
| | Oxygen | 1 | 2024 | 998 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 399 | 0.030 |
Why?
| | Hemostasis | 1 | 1998 | 100 | 0.030 |
Why?
| | Plasminogen Activators | 1 | 1997 | 7 | 0.030 |
Why?
| | Vascular Resistance | 1 | 1998 | 372 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 2018 | 170 | 0.030 |
Why?
| | Gait | 2 | 1997 | 317 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 6099 | 0.030 |
Why?
| | Movement Disorders | 1 | 1997 | 69 | 0.030 |
Why?
| | United States | 1 | 2014 | 16313 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 1997 | 106 | 0.030 |
Why?
| | Chromium | 1 | 1996 | 18 | 0.030 |
Why?
| | Weight Lifting | 1 | 1996 | 31 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 590 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2625 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1281 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2946 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 348 | 0.030 |
Why?
| | Swimming | 3 | 1999 | 54 | 0.030 |
Why?
| | Hypoxia | 1 | 2021 | 1208 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 164 | 0.020 |
Why?
| | Menopause | 1 | 1997 | 328 | 0.020 |
Why?
| | Brain Ischemia | 1 | 1997 | 362 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1776 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 1997 | 395 | 0.020 |
Why?
| | Tunica Media | 2 | 2001 | 38 | 0.020 |
Why?
| | Sex Factors | 1 | 1996 | 2136 | 0.020 |
Why?
| | Animals | 3 | 2024 | 38410 | 0.020 |
Why?
| | Cardiac Output | 2 | 1998 | 179 | 0.020 |
Why?
| | Bone Density | 1 | 2010 | 493 | 0.010 |
Why?
| | Prospective Studies | 4 | 2001 | 8164 | 0.010 |
Why?
| | Stroke Volume | 2 | 1998 | 658 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 65 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 89 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 154 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 166 | 0.010 |
Why?
| | Blood Viscosity | 1 | 2001 | 19 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2002 | 277 | 0.010 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| | Habits | 1 | 2001 | 52 | 0.010 |
Why?
| | Thigh | 1 | 2000 | 48 | 0.010 |
Why?
| | Thinness | 1 | 2000 | 100 | 0.010 |
Why?
| | Mexico | 1 | 2001 | 233 | 0.010 |
Why?
| | Elasticity | 1 | 2000 | 189 | 0.010 |
Why?
| | Erythrocyte Volume | 1 | 1999 | 6 | 0.010 |
Why?
| | Plasma Volume | 1 | 1999 | 20 | 0.010 |
Why?
| | Femur | 1 | 2001 | 261 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 494 | 0.010 |
Why?
| | Supine Position | 1 | 1998 | 38 | 0.010 |
Why?
| | Posture | 1 | 1999 | 197 | 0.010 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 153 | 0.010 |
Why?
| | Hematocrit | 1 | 1997 | 109 | 0.010 |
Why?
| | Rest | 1 | 1997 | 127 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1997 | 85 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1342 | 0.010 |
Why?
| | Ventricular Fibrillation | 1 | 1997 | 64 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1997 | 114 | 0.010 |
Why?
| | Hyperlipidemias | 1 | 1997 | 120 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1997 | 225 | 0.010 |
Why?
| | Equipment Design | 1 | 1997 | 527 | 0.010 |
Why?
| | Tachycardia, Ventricular | 1 | 1997 | 182 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1550 | 0.010 |
Why?
| | Electrocardiography | 1 | 1998 | 675 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1569 | 0.010 |
Why?
| | Stroke | 1 | 2002 | 1287 | 0.010 |
Why?
| | Heart Arrest | 1 | 1997 | 412 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 2110 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1997 | 936 | 0.010 |
Why?
| | Length of Stay | 1 | 1997 | 1371 | 0.010 |
Why?
| | Smoking | 1 | 1997 | 1483 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2003 | 17560 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|